NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.88 -0.12 (-0.15%) GOLD FUTURES
2,316.30 +5.30 (+0.23%) DOW
38,233.05 +329.76 (+0.87%) Bitcoin GBP
47,346.31 +716.76 (+1.54%)
Avacta Group Plc (AVCT.L)
| Previous close | 46.75 |
| Open | 45.99 |
| Bid | 46.00 x 0 |
| Ask | 49.00 x 0 |
| Day's range | 45.00 - 47.00 |
| 52-week range | 43.00 - 166.98 |
| Volume | |
| Avg. volume | 3,423,154 |
| Market cap | 166.955M |
| Beta (5Y monthly) | 1.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.16 |
| Earnings date | 30 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 92.33 |
Simply Wall St.Avacta Group (LON:AVCT) investors are sitting on a loss of 82% if they invested three years ago
As an investor, mistakes are inevitable. But you want to avoid the really big losses like the plague. So spare a...
Globe NewswireAvacta Group - AVA6000 Abstract Release by AACR and Full Presentation Update
5 April 2024 Avacta Group plc(“Avacta” or “the Group” or “the Company”) AVA6000 Abstract Release by AACR and Full Presentation Update Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces that the abstract of the poster to be presented at the American Association of Cancer Research (“AACR”) Annual Meeting in San Diego, California on Tuesday 9 April has now been released by AACR. The poster presentation will
- Globe Newswire
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024
5 March 2024 Avacta Group plc (“Avacta” or “the Group” or “the Company”) Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, today announces updated clinical data from the First-in-Human Phase 1 trial of the peptide dru
